The patients with TNBC revealed higher plasma ADA2 activities at advanced stages of cancer development than in the initial stages and exhibited low ADA1/ADA2 ratio, while patients with HR+HER2+ and HR+HER2- breast cancers at the same stages showed opposite trends. This evidence concerns the gene ERBB2 and breast cancer.